Summary

In the BRIDGE trial, bridging with low molecular weight heparin in patients with atrial fibrillation who underwent surgery or an invasive procedure that required warfarin interruption resulted in similar rates of arterial thromboembolism but significantly higher rates of minor and major bleeding.